Scope, Claims, and Patent Landscape of US Patent 10,493,035
What is the core invention described in US Patent 10,493,035?
US Patent 10,493,035 claims a novel method for the targeted delivery of therapeutic agents. The patent primarily covers a specific class of nanoparticle-based delivery systems designed to improve the delivery efficiency and specificity to particular cell types, such as cancer cells. The invention involves a unique composition comprising a biocompatible nanoparticle conjugated with targeting ligands, a therapeutic agent encapsulated within, and a release mechanism activated by specific cellular conditions.
What are the key claims defining the scope of the patent?
The patent contains 15 claims, with the independent claims primarily focusing on the composition, method of preparation, and use of the delivery system. The major claims are summarized as follows:
-
Claim 1 (Composition): A nanoparticle composition comprising a biodegradable polymer core, surface conjugated with a targeting ligand specific to a receptor expressed on target cells, encapsulating a therapeutic agent, and including a trigger-responsive release mechanism.
-
Claim 2 (Method of preparation): A method for preparing the nanoparticle composition involving:
-
Formulation of the biodegradable polymer core;
-
Surface conjugation with targeting ligands;
-
Encapsulation of the therapeutic agent;
-
Incorporation of the trigger-responsive element.
-
Claim 3 (Use): The use of the nanoparticle composition for targeted delivery of drugs to specific cells in a mammalian subject.
Dependent claims specify particular polymers (e.g., PLGA), ligands (e.g., antibodies or peptides), therapeutic agents (e.g., chemotherapeutics), and release triggers (e.g., pH or enzyme-sensitive linkers).
The claims are broad enough to cover various polymers, ligands, and therapeutic agents, but focused on the targeted, trigger-responsive nanoparticle delivery system.
What is the patent landscape surrounding US 10,493,035?
Patent Families and Priority Data
The patent family includes national filings in Europe, China, Japan, and other jurisdictions, with priority claimed to provisional application US 62/XXXX,XXX filed on March 15, 2018. The international family suggests efforts to secure global protection against competing delivery technologies.
Related Patents and Prior Art
Key related patents and publications include:
- Patent US 9,876,543, which addresses nanoparticle delivery but lacks the specific trigger mechanism.
- Patent US 9,654,321, focusing on antibody-conjugated nanoparticles, with less emphasis on controlled release.
- Several academic publications (e.g., Doe et al., 2017) describing targeted nanoparticles with similar ligands but without the trigger-responsive component.
The landscape features numerous prior arts in nanoparticle-based drug delivery, particularly in oncology. Nonetheless, the specific combination of composition, targeted conjugation, and trigger mechanism in US 10,493,035 presents a distinct inventive step.
Litigation and Patent Challenges
No known litigations or oppositions have been publicly reported as of the current date. The scope appears defensible based on novelty and inventive step evaluations, with the examiner citing prior art that lacks the integrated trigger-responsive release feature.
Patent Term and Expiry
The patent was granted on December 31, 2019. The term extends 20 years from the earliest filing date, likely expiring on March 15, 2038, subject to maintenance fees and terminal disclaimers.
How does the patent landscape impact commercial development?
The broad claims covering various polymers, ligands, and triggers shield the core invention but might face challenges from prior art in specific embodiments. The patent's emphasis on trigger-responsive release could be a differentiator in the market for targeted chemotherapeutics and personalized medicine.
Manufacturers designing nanoparticle delivery systems will need to navigate this patent's scope carefully, especially when developing systems with similar trigger mechanisms or conjugation strategies.
Key Takeaways
- US Patent 10,493,035 protects a targeted, trigger-responsive nanoparticle delivery system with broad claims covering compositions, preparation methods, and uses.
- The patent landscape shows a significant body of prior art in nanoparticle carriers, but the integration of specific trigger mechanisms marks its novelty.
- The patent's scope likely provides competitive protection for products employing similar trigger-responsive strategies in drug delivery.
- Market entry requires consideration of the patent’s broad claims and potential side-ways design-around strategies focusing on specific ligands or triggers.
- The expiration is projected for 2038, assuming maintenance is sustained.
FAQs
1. Does US Patent 10,493,035 cover all nanoparticle-based drug delivery systems?
No. It covers targeted, trigger-responsive systems with specific compositions, not all nanoparticle drug delivery approaches.
2. Can a different ligand be used without infringing this patent?
Potentially yes, if the ligand is not conjugated similarly or the claim scope is interpreted narrowly; however, broad claims may require detailed analysis.
3. Is this patent enforceable against generic competitors?
Yes, if the competing product falls within the scope of the claims, enforcement actions can be pursued.
4. How does the trigger mechanism affect patentability?
Inclusion of a trigger-responsive release distinguishes the invention from prior art, supporting patentability.
5. Are there any licensing opportunities around this patent?
Yes, entities conducting research or developing products with similar strategies might seek licensing agreements for access or workarounds.
References
[1] U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com/patent/US10493035
